Skip to main content
Top
Published in: Journal of Bone and Mineral Metabolism 1/2012

01-01-2012 | Original Article

FGF23 analysis of a Chinese family with autosomal dominant hypophosphatemic rickets

Authors: Yue Sun, Ou Wang, Weibo Xia, Yan Jiang, Mei Li, Xiaoping Xing, Yingying Hu, Huaicheng Liu, Xunwu Meng, Xueying Zhou

Published in: Journal of Bone and Mineral Metabolism | Issue 1/2012

Login to get access

Abstract

Autosomal dominant hypophosphatemic rickets (ADHR; MIM 193100) is a hereditary disorder characterized by isolated renal phosphate wasting, hypophosphatemia, and inappropriately normal 1,25-dihydroxyvitamin D3 levels. Recent studies have shown that the fibroblast growth factor 23 (FGF23) gene is responsible for this disease. FGF23 protein is a phosphaturic factor that is elevated in several diseases associated with hypophosphatemia and rickets but varies with disease status in ADHR. In the present study we observed a Chinese family of Han ethnic origin diagnosed with ADHR. The proband is a 30-year-old woman with no history of rickets but with multiple tooth abscesses as a young adult. She presented with progressive painful swelling of the left ankle after a blunt trauma at 26 years of age. She developed back pain, generalized weakness, and fatigue, and she could barely walk at age 27. She was found to have severe hypophosphatemia, low ratio of phosphorus tubule maximum (TmP) to glomerular filtration rate (GFR) (TmP/GFR), and elevated alkaline phosphatase at age 28. Her brother, 26 years old, presented with fatigue at 24 years of age and is normophosphatemic. The parents of this family had no history of rickets or hypophosphatemia. Direct sequence analysis of genomic DNA demonstrated a single heterozygous c.527G>A (p.R176Q) mutation in the FGF23 gene in three family members, including the proband, her brother, and their mother. Intact FGF23 assay of seven time points during the oral phosphate loading test showed no significant relationship between intact FGF23 and serum phosphorus levels of the subject with ADHR and a control. It is probably the first report of a Chinese family with ADHR.
Literature
1.
go back to reference Econs MJ, McEnery PT (1997) Autosomal dominant hypophosphatemic rickets/osteomalacia: clinical characterization of a novel renal phosphate-wasting disorder. J Clin Endocr Metab 82:674–681PubMedCrossRef Econs MJ, McEnery PT (1997) Autosomal dominant hypophosphatemic rickets/osteomalacia: clinical characterization of a novel renal phosphate-wasting disorder. J Clin Endocr Metab 82:674–681PubMedCrossRef
2.
go back to reference Bianchine JW, Stambler AA, Harrison HE (1971) Familial hypophosphatemic rickets showing autosomal dominant inheritance. Birth Defects Orig Artic Ser VII:287–294 Bianchine JW, Stambler AA, Harrison HE (1971) Familial hypophosphatemic rickets showing autosomal dominant inheritance. Birth Defects Orig Artic Ser VII:287–294
3.
go back to reference Imel EAHS, Econs MJ (2007) FGF23 concentrations vary with disease status in autosomal dominant hypophosphatemic rickets. J Bone Miner Res 22:520–526PubMedCrossRef Imel EAHS, Econs MJ (2007) FGF23 concentrations vary with disease status in autosomal dominant hypophosphatemic rickets. J Bone Miner Res 22:520–526PubMedCrossRef
4.
go back to reference Negri AL, Negrotti T, Alonso G, Pasqualini T (2004) Different forms of clinical presentation of an autosomal dominant hypophosphatemic rickets caused by a FGF23 mutation in one family. Medicina (B Aires) 64:103–106 Negri AL, Negrotti T, Alonso G, Pasqualini T (2004) Different forms of clinical presentation of an autosomal dominant hypophosphatemic rickets caused by a FGF23 mutation in one family. Medicina (B Aires) 64:103–106
5.
go back to reference Consortium ADHR (2000) Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23. Nat Genet 26:345–348CrossRef Consortium ADHR (2000) Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23. Nat Genet 26:345–348CrossRef
6.
go back to reference White KE, Carn G, Lorenz-Depiereux B, Benet-Pages A, Strom TM, Econs MJ (2001) Autosomal-dominant hypophosphatemic rickets (ADHR) mutations stabilize FGF-23. Kidney Int 60:2079–2086PubMedCrossRef White KE, Carn G, Lorenz-Depiereux B, Benet-Pages A, Strom TM, Econs MJ (2001) Autosomal-dominant hypophosphatemic rickets (ADHR) mutations stabilize FGF-23. Kidney Int 60:2079–2086PubMedCrossRef
7.
go back to reference Bai XY, Miao D, Goltzman D, Karaplis AC (2003) The autosomal dominant hypophosphatemic rickets r176q mutation in fibroblast growth factor 23 resists proteolytic cleavage and enhances in vivo biological potency. J Biol Chem 278:9843–9849PubMedCrossRef Bai XY, Miao D, Goltzman D, Karaplis AC (2003) The autosomal dominant hypophosphatemic rickets r176q mutation in fibroblast growth factor 23 resists proteolytic cleavage and enhances in vivo biological potency. J Biol Chem 278:9843–9849PubMedCrossRef
8.
go back to reference Kiela PR, Ghishan FK (2009) Recent advances in the renal–skeletal–gut axis that controls phosphate homeostasis. Lab Invest 89:7–14PubMedCrossRef Kiela PR, Ghishan FK (2009) Recent advances in the renal–skeletal–gut axis that controls phosphate homeostasis. Lab Invest 89:7–14PubMedCrossRef
9.
go back to reference Tiosano D, Hochberg Z (2009) Hypophosphatemia: the common denominator of all rickets. J Bone Miner Metab 27:392–401PubMedCrossRef Tiosano D, Hochberg Z (2009) Hypophosphatemia: the common denominator of all rickets. J Bone Miner Metab 27:392–401PubMedCrossRef
10.
go back to reference Weber TJ, Liu S, Indridason OS, Quarles LD (2003) Serum FGF23 levels in normal and disordered phosphorus homeostasis. J Bone Miner Res 18:1227–1234PubMedCrossRef Weber TJ, Liu S, Indridason OS, Quarles LD (2003) Serum FGF23 levels in normal and disordered phosphorus homeostasis. J Bone Miner Res 18:1227–1234PubMedCrossRef
11.
go back to reference Jonsson KB, Zahradnik R, Larsson T, White KE, Sugimoto T, Imanishi Y, Yamamoto T, Hampson G, Koshiyama H, Ljunggren O, Oba K, Yang IM, Miyauchi A, Econs MJ, Lavigne J, Jüppner H (2003) Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia. N Engl J Med 348:1656–1663PubMedCrossRef Jonsson KB, Zahradnik R, Larsson T, White KE, Sugimoto T, Imanishi Y, Yamamoto T, Hampson G, Koshiyama H, Ljunggren O, Oba K, Yang IM, Miyauchi A, Econs MJ, Lavigne J, Jüppner H (2003) Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia. N Engl J Med 348:1656–1663PubMedCrossRef
12.
go back to reference Bijvoet OL, Morgan DB, Fourman P (1969) The assessment of phosphate reabsorption. Clin Chim Acta 26:15–24PubMedCrossRef Bijvoet OL, Morgan DB, Fourman P (1969) The assessment of phosphate reabsorption. Clin Chim Acta 26:15–24PubMedCrossRef
13.
go back to reference Yamazaki Y, Okazaki R, Shibata M, Hasegawa Y, Satoh K, Tajima T, Takeuchi Y, Fujita T, Nakahara K, Yamashita T, Fukumoto S (2002) Increased circulatory level of biologically active full-length Fgf-23 in patients with hypophosphatemic rickets/osteomalacia. J Clin Endocrinol Metab 87:4957–4960PubMedCrossRef Yamazaki Y, Okazaki R, Shibata M, Hasegawa Y, Satoh K, Tajima T, Takeuchi Y, Fujita T, Nakahara K, Yamashita T, Fukumoto S (2002) Increased circulatory level of biologically active full-length Fgf-23 in patients with hypophosphatemic rickets/osteomalacia. J Clin Endocrinol Metab 87:4957–4960PubMedCrossRef
14.
go back to reference Imel EA, Peacock M, Pitukcheewanont P, Heller HJ, Ward LM, Shulman D, Kassem M, Rackoff P, Zimering M, Dalkin A, Drobny E, Colussi G, Shaker JL, Hoogendoorn EH, Hui SL, Econs MJ (2006) Sensitivity of fibroblast growth factor 23 measurements in tumor-induced osteomalacia. J Clin Endocrinol Metab 91:2055–2061PubMedCrossRef Imel EA, Peacock M, Pitukcheewanont P, Heller HJ, Ward LM, Shulman D, Kassem M, Rackoff P, Zimering M, Dalkin A, Drobny E, Colussi G, Shaker JL, Hoogendoorn EH, Hui SL, Econs MJ (2006) Sensitivity of fibroblast growth factor 23 measurements in tumor-induced osteomalacia. J Clin Endocrinol Metab 91:2055–2061PubMedCrossRef
15.
go back to reference Xia W, Meng X, Jiang Y, Li M, Xing X, Pang L, Wang O, Pei Y, Yu LY, Sun Y, Hu Y, Zhou X (2007) Three novel mutations of the PHEX gene in three Chinese families with X-linked dominant hypophosphatemic rickets. Calcif Tissue Int 81:415–420PubMedCrossRef Xia W, Meng X, Jiang Y, Li M, Xing X, Pang L, Wang O, Pei Y, Yu LY, Sun Y, Hu Y, Zhou X (2007) Three novel mutations of the PHEX gene in three Chinese families with X-linked dominant hypophosphatemic rickets. Calcif Tissue Int 81:415–420PubMedCrossRef
16.
go back to reference Gribaa M, Younes M, Bouyacoub Y, Korbaa W, Ben Charfeddine I, Touzi M, Adala L, Mamay O, Bergaoui N, Saad A (2009) An autosomal dominant hypophosphatemic rickets phenotype in a Tunisian family caused by a new FGF23 missense mutation. J Bone Miner Metab 28:111–115. doi:10.1007/s00774-009-0111-5 PubMedCrossRef Gribaa M, Younes M, Bouyacoub Y, Korbaa W, Ben Charfeddine I, Touzi M, Adala L, Mamay O, Bergaoui N, Saad A (2009) An autosomal dominant hypophosphatemic rickets phenotype in a Tunisian family caused by a new FGF23 missense mutation. J Bone Miner Metab 28:111–115. doi:10.​1007/​s00774-009-0111-5 PubMedCrossRef
17.
go back to reference Wilson DR, York SE, Jaworski ZF, Yendt ER (1965) Studies in hypophosphatemic vitamin D-refractory osteomalacia in adults: oral phosphate supplements as an adjunct to therapy. Medicine (Baltim) 44:99–134 Wilson DR, York SE, Jaworski ZF, Yendt ER (1965) Studies in hypophosphatemic vitamin D-refractory osteomalacia in adults: oral phosphate supplements as an adjunct to therapy. Medicine (Baltim) 44:99–134
18.
go back to reference Harrison HE, Harrison HC, Lifshitz F, Johnson AD (1966) Growth disturbance in hereditary hypophosphatemia. Am J Dis Child 112:290–297PubMed Harrison HE, Harrison HC, Lifshitz F, Johnson AD (1966) Growth disturbance in hereditary hypophosphatemia. Am J Dis Child 112:290–297PubMed
19.
20.
go back to reference Kruse K, Woelfel D, Storm TM (2001) Loss of renal phosphate wasting in a child with autosomal dominant hypophosphatemic rickets caused by a FGF23 mutation. Horm Res 55:305–308PubMedCrossRef Kruse K, Woelfel D, Storm TM (2001) Loss of renal phosphate wasting in a child with autosomal dominant hypophosphatemic rickets caused by a FGF23 mutation. Horm Res 55:305–308PubMedCrossRef
21.
go back to reference Yamashita T (2005) Structural and biochemical properties of fibroblast growth factor 23. Ther Apher Dial 9:313–318PubMedCrossRef Yamashita T (2005) Structural and biochemical properties of fibroblast growth factor 23. Ther Apher Dial 9:313–318PubMedCrossRef
22.
go back to reference Mirams M, Robinson BG, Mason RS, Nelson AE (2004) Bone as a source of FGF23: regulation by phosphate? Bone (NY) 35:1192–1199CrossRef Mirams M, Robinson BG, Mason RS, Nelson AE (2004) Bone as a source of FGF23: regulation by phosphate? Bone (NY) 35:1192–1199CrossRef
23.
go back to reference Liu S, Gupta A, Quarles LD (2007) Emerging role of fibroblast growth factor 23 in a bone-kidney axis regulating systemic phosphate homeostasis and extracellular matrix mineralization. Curr Opin Nephrol Hypertens 16:329–335PubMedCrossRef Liu S, Gupta A, Quarles LD (2007) Emerging role of fibroblast growth factor 23 in a bone-kidney axis regulating systemic phosphate homeostasis and extracellular matrix mineralization. Curr Opin Nephrol Hypertens 16:329–335PubMedCrossRef
24.
go back to reference Endo I, Fukumoto S, Ozono K, Namba N, Tanaka H, Inoue D, Minagawa M, Sugimoto T, Yamauchi M, Michigami T, Matsumoto T (2008) Clinical usefulness of measurement of fibroblast growth factor 23 (FGF23) in hypophosphatemic patients. Proposal of diagnostic criteria using FGF23 measurement. Bone (NY) 42:1235–1239CrossRef Endo I, Fukumoto S, Ozono K, Namba N, Tanaka H, Inoue D, Minagawa M, Sugimoto T, Yamauchi M, Michigami T, Matsumoto T (2008) Clinical usefulness of measurement of fibroblast growth factor 23 (FGF23) in hypophosphatemic patients. Proposal of diagnostic criteria using FGF23 measurement. Bone (NY) 42:1235–1239CrossRef
25.
go back to reference Laroche M, Boyer JF, Jahafar H, Allard J, Tack I (2009) Normal FGF23 levels in adult idiopathic phosphate diabetes. Calcif Tissue Int 84:112–117PubMedCrossRef Laroche M, Boyer JF, Jahafar H, Allard J, Tack I (2009) Normal FGF23 levels in adult idiopathic phosphate diabetes. Calcif Tissue Int 84:112–117PubMedCrossRef
26.
go back to reference Ito N, Fukumoto S, Takeuchi Y, Takeda S, Suzuki H, Yamashita T, Fujita T (2007) Effect of acute changes of serum phosphate on fibroblast growth factor (FGF)23 levels in humans. J Bone Miner Metab 25:419–422PubMedCrossRef Ito N, Fukumoto S, Takeuchi Y, Takeda S, Suzuki H, Yamashita T, Fujita T (2007) Effect of acute changes of serum phosphate on fibroblast growth factor (FGF)23 levels in humans. J Bone Miner Metab 25:419–422PubMedCrossRef
Metadata
Title
FGF23 analysis of a Chinese family with autosomal dominant hypophosphatemic rickets
Authors
Yue Sun
Ou Wang
Weibo Xia
Yan Jiang
Mei Li
Xiaoping Xing
Yingying Hu
Huaicheng Liu
Xunwu Meng
Xueying Zhou
Publication date
01-01-2012
Publisher
Springer Japan
Published in
Journal of Bone and Mineral Metabolism / Issue 1/2012
Print ISSN: 0914-8779
Electronic ISSN: 1435-5604
DOI
https://doi.org/10.1007/s00774-011-0285-5

Other articles of this Issue 1/2012

Journal of Bone and Mineral Metabolism 1/2012 Go to the issue